The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting

Nitin Babulal Bagul, Jamie J Kirkham

Research output: Contribution to journalReview articlepeer-review

Abstract

The aim of this study was to assess the quality of reporting of harms in hypertension clinical trials identified from the Cochrane Database using the Consolidated Standards of Reporting Trials (CONSORT) extension for harms reporting. Forty-one hypertension trials were included in the study. On average trials reported less than half of the items recommended by the CONSORT extension for harms (mean 9.83 items; 95% confidence interval = 8.06, 11.60). Trialists need to address the perceived shortcomings in measurement, analysis, and reporting of harms data so that the available trial data can be considered as a balanced and reliable source of evidence.

Original languageEnglish
Pages (from-to)548-54
Number of pages7
JournalClinical and Experimental Hypertension
Volume34
Issue number8
DOIs
Publication statusPublished - 2012

Keywords

  • Antihypertensive Agents/administration & dosage
  • Confidence Intervals
  • Humans
  • Hypertension/drug therapy
  • Practice Guidelines as Topic/standards
  • Randomized Controlled Trials as Topic/standards
  • Research Design
  • United Kingdom
  • Writing/standards

Fingerprint

Dive into the research topics of 'The reporting of harms in randomized controlled trials of hypertension using the CONSORT criteria for harm reporting'. Together they form a unique fingerprint.

Cite this